(NP (NP (NN Glucocorticoid) (NNS receptors)) (PP (IN in) (NP (JJ systemic) (NN lupus) (NN erythematosus))) (. .))
(S (S-COOD (S (NP-SBJ (NNS Glucocorticosteroids)) (VP (VBP remain) (NP-PRD (NP (DT the) (JJ major) (NN treatment) (NN modality)) (PP (IN for) (NP (NP (JJ systemic) (NN lupus) (NN erythematosus)) (PRN (-LRB- -LRB-) (NP (NN SLE)) (-RRB- -RRB-))))))) (, ,) (CC but) (S (NP-SBJ (NP (PRP$ their) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (VBZ is) (ADJP-PRD (JJ unclear))))) (. .))
(S (PP-TMP (IN Over) (NP (DT the) (JJ past) (NN decade))) (NP-SBJ (NP (PRP it)) (SBAR (-NONE- *EXP*-94))) (VP (VBZ has) (VP (VBN become) (ADJP-PRD (JJ clear)) (SBAR-94 (IN that) (S (NP-SBJ (NN glucocorticosteroid) (NNS receptors)) (VP (VBP play) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN glucocorticosteroid) (NN action)))))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBD studied) (NP (NP (NN glucocorticosteroid) (NN receptor) (NP-COOD (NP (NN density)) (CC and) (NP (NN affinity)))) (PP (IN on) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))) (PP (IN by) (NP (DT the) (NN glucocorticosteroid) (NN binding) (NN assay))) (PP-COOD (PP (IN in) (NP (NP (CD 33) (NNS patients)) (PP (IN with) (NP (NN SLE))) (SBAR (WHNP-40 (WP who)) (S (NP-SBJ (-NONE- *T*-40)) (VP (VBD had) (VP (VBN taken) (NP (DT no) (NN glucocorticosteroid)) (PP-TMP (IN for) (NP (DT the) (JJ previous) (CD 6) (NNS months))))))))) (CC and) (PP (IN in) (NP (CD 32) (JJ healthy) (NNS controls))))) (. .))
(S (NP-SBJ-41 (NP (NNS Patients) (POS ')) (NN disease) (NN activity)) (VP (VBD was) (VP (VBN measured) (NP (-NONE- *-41)) (PP (IN by) (NP-LGS (NP (DT the) (NN SLE) (NN Disease) (NN Activity) (NN Index)) (PRN (-LRB- -LRB-) (NP (NN SLEDAI)) (-RRB- -RRB-)))))) (. .))
(S (NP-SBJ (NP (NN Glucocorticosteroid) (NNS receptors)) (PP (IN on) (NP (NP (NNS leukocytes)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NN SLE))))))) (VP (VBD were) (ADJP-PRD (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (FRAG (PP (IN in) (NP (JJ healthy) (NNS controls)))))) (PRN (-LRB- -LRB-) (FRAG (NP-COOD (NP (QP (CD 4419) (CC (- +)) (CD 306))) (CC vs) (NP (QP (CD 3369) (CC (- +)) (CD 196))))) (, ,) (S (NP-SBJ (NN p)) (ADJP-PRD (ADJP (JJR less)) (PP (IN than) (NP (CD 0.005))))) (-RRB- -RRB-)))) (. .))
(S (NP-SBJ (DT The) (NN binding) (NN affinity)) (VP (VBD was) (RB not) (ADJP-PRD (JJ different)) (PP (IN between) (NP-COOD (NP (NNS patients)) (CC and) (NP (NNS controls))))) (. .))
(S (NP-SBJ (EX There)) (VP (VBD was) (NP-PRD (DT no) (NN correlation)) (PP (IN between) (NP-COOD (NP (NN glucocorticosteroid) (NN receptor) (NN number)) (CC and) (NP (NN SLE) (NN disease) (NN activity))))) (. .))
